Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

166 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Inadequate health-related quality of life assessment and reporting in phase III clinical trials of immune checkpoint inhibitors in solid cancers: A systematic review.
Servetto A, Salomone F, Di Costanzo F, Iuliano R, Marandino L, Napolitano F, Santaniello A, De Placido P, De Placido S, Di Maio M, Formisano L, Bianco R. Servetto A, et al. Among authors: formisano l. Crit Rev Oncol Hematol. 2022 Apr;172:103649. doi: 10.1016/j.critrevonc.2022.103649. Epub 2022 Mar 5. Crit Rev Oncol Hematol. 2022. PMID: 35259486 Review.
Sphingosine kinase 1 overexpression contributes to cetuximab resistance in human colorectal cancer models.
Rosa R, Marciano R, Malapelle U, Formisano L, Nappi L, D'Amato C, D'Amato V, Damiano V, Marfè G, Del Vecchio S, Zannetti A, Greco A, De Stefano A, Carlomagno C, Veneziani BM, Troncone G, De Placido S, Bianco R. Rosa R, et al. Among authors: formisano l. Clin Cancer Res. 2013 Jan 1;19(1):138-47. doi: 10.1158/1078-0432.CCR-12-1050. Epub 2012 Nov 19. Clin Cancer Res. 2013. PMID: 23166225
Toll-like receptor 9 agonist IMO cooperates with everolimus in renal cell carcinoma by interfering with tumour growth and angiogenesis.
Damiano V, Rosa R, Formisano L, Nappi L, Gelardi T, Marciano R, Cozzolino I, Troncone G, Agrawal S, Veneziani BM, De Placido S, Bianco R, Tortora G. Damiano V, et al. Among authors: formisano l. Br J Cancer. 2013 Apr 30;108(8):1616-23. doi: 10.1038/bjc.2013.153. Epub 2013 Apr 9. Br J Cancer. 2013. PMID: 23571736 Free PMC article.
The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models.
D'Amato V, Rosa R, D'Amato C, Formisano L, Marciano R, Nappi L, Raimondo L, Di Mauro C, Servetto A, Fusciello C, Veneziani BM, De Placido S, Bianco R. D'Amato V, et al. Among authors: formisano l. Br J Cancer. 2014 Jun 10;110(12):2887-95. doi: 10.1038/bjc.2014.241. Epub 2014 May 13. Br J Cancer. 2014. PMID: 24823695 Free PMC article.
Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells.
D'Amato C, Rosa R, Marciano R, D'Amato V, Formisano L, Nappi L, Raimondo L, Di Mauro C, Servetto A, Fulciniti F, Cipolletta A, Bianco C, Ciardiello F, Veneziani BM, De Placido S, Bianco R. D'Amato C, et al. Among authors: formisano l. Br J Cancer. 2014 Sep 9;111(6):1168-79. doi: 10.1038/bjc.2014.421. Epub 2014 Aug 5. Br J Cancer. 2014. PMID: 25093491 Free PMC article.
Powerful anti-tumor and anti-angiogenic activity of a new anti-vascular endothelial growth factor receptor 1 peptide in colorectal cancer models.
Cicatiello V, Apicella I, Tudisco L, Tarallo V, Formisano L, Sandomenico A, Kim Y, Bastos-Carvalho A, Orlandi A, Ambati J, Ruvo M, Bianco R, De Falco S. Cicatiello V, et al. Among authors: formisano l. Oncotarget. 2015 Apr 30;6(12):10563-76. doi: 10.18632/oncotarget.3384. Oncotarget. 2015. PMID: 25868854 Free PMC article.
Mechanisms of lapatinib resistance in HER2-driven breast cancer.
D'Amato V, Raimondo L, Formisano L, Giuliano M, De Placido S, Rosa R, Bianco R. D'Amato V, et al. Among authors: formisano l. Cancer Treat Rev. 2015 Dec;41(10):877-83. doi: 10.1016/j.ctrv.2015.08.001. Epub 2015 Aug 8. Cancer Treat Rev. 2015. PMID: 26276735 Review.
Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status.
Formisano L, D'Amato V, Servetto A, Brillante S, Raimondo L, Di Mauro C, Marciano R, Orsini RC, Cosconati S, Randazzo A, Parsons SJ, Montuori N, Veneziani BM, De Placido S, Rosa R, Bianco R. Formisano L, et al. Oncotarget. 2015 Sep 22;6(28):26090-103. doi: 10.18632/oncotarget.4636. Oncotarget. 2015. PMID: 26325669 Free PMC article.
Everolimus induces Met inactivation by disrupting the FKBP12/Met complex.
Raimondo L, D'Amato V, Servetto A, Rosa R, Marciano R, Formisano L, Di Mauro C, Orsini RC, Cascetta P, Ciciola P, De Maio AP, Di Renzo MF, Cosconati S, Bruno A, Randazzo A, Napolitano F, Montuori N, Veneziani BM, De Placido S, Bianco R. Raimondo L, et al. Among authors: formisano l. Oncotarget. 2016 Jun 28;7(26):40073-40084. doi: 10.18632/oncotarget.9484. Oncotarget. 2016. PMID: 27223077 Free PMC article.
166 results